MiNK Therapeutics, Inc.(INKT)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
INKT Stock Analysis & AI Quality Score
AI stock analysis and institutional research for MiNK Therapeutics, Inc. (INKT), a Healthcare sector company. INKT is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), MiNK Therapeutics, Inc. reports net income of $-2.7M, free cash flow of $-1.7M. Top institutional holders of INKT by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, GEODE CAPITAL MANAGEMENT,, Longbow Finance SA, based on the most recent SEC filings. INKT trades on the Nasdaq exchange and files with the SEC under CIK 1840229. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate INKT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for MiNK Therapeutics, Inc. directly from SEC EDGAR.
Net Income
Q1 2026
$-2.7M
Free Cash Flow
Q1 2026
$-1.7M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Net Income
-15.9% YoYOperating Income
-12.0% YoYEPS (Diluted)
-2.4% YoYTotal Assets
+148.9% YoYOp. Cash Flow
+38.0% YoY| Metric | FY 2025 | FY 2024 | FY 2022 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Net Income | $-12.5M -15.9% | $-10.8M +61.5% | $-28.0M -72.4% | $-16.2M | — |
| Operating Income | $-12.6M -12.0% | $-11.3M +63.5% | $-30.9M -111.4% | $-14.6M | — |
| EPS (Diluted) | $-2.93 -2.4% | $-2.86 -244.6% | $-0.83 | — | — |
| Total Assets | $14.2M +148.9% | $5.7M -73.4% | $21.5M +371.4% | $4.6M | — |
| Operating Cash Flow | $-5.9M +38.0% | $-9.6M +49.4% | $-18.9M -126.3% | $-8.3M | — |
AI Insight: INKT Ratio Trends
MiNK remains deeply unprofitable with ROA improving from -98.0% in Q3 2024 to -73.1% in Q4 2025, but sustainability unclear.
• ROA improved 24.9pp from Q3 2024 (-98.0%) to Q4 2025 (-73.1%), signaling reduced loss intensity.
⚠ Company remains deeply unprofitable across all measured periods; ROA near -73% indicates severe cash burn.
⚠ All other key metrics (OpMargin, NPM, ROE, ROIC, D/E) absent from dataset; limited visibility on operational trajectory.
Get alerted when INKT's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for MiNK Therapeutics, Inc. including:
Top Institutional Holders of INKT
VANGUARD CAPITAL MANAGEMENT LLC
$625.1K59,364 shGEODE CAPITAL MANAGEMENT, LLC
$182.7K17,345 shLongbow Finance SA
$175.5K16,667 shUBS Group AG
$160.1K15,202 shVANGUARD FIDUCIARY TRUST CO
$87.3K8,287 shBlackRock, Inc.
$65.3K6,203 shSteward Partners Investment Advisory, LLC
$21.1K2,000 shPaladin Partners, LLC
$10.5K1,000 shAnnis Gardner Whiting Capital Advisors, LLC
$2.1K200 shTower Research Capital LLC (TRC)
$1.6K156 sh
| Fund | Value | Shares |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $625.1K | 59,364 |
| GEODE CAPITAL MANAGEMENT, LLC | $182.7K | 17,345 |
| Longbow Finance SA | $175.5K | 16,667 |
| UBS Group AG | $160.1K | 15,202 |
| VANGUARD FIDUCIARY TRUST CO | $87.3K | 8,287 |
| BlackRock, Inc. | $65.3K | 6,203 |
| Steward Partners Investment Advisory, LLC | $21.1K | 2,000 |
| Paladin Partners, LLC | $10.5K | 1,000 |
| Annis Gardner Whiting Capital Advisors, LLC | $2.1K | 200 |
| Tower Research Capital LLC (TRC) | $1.6K | 156 |
More Healthcare Companies
View all Healthcare →Put INKT on your watchlist
Track score changes the day MiNK Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is INKT a good stock to buy?
13F Pro's AI-powered analysis of MiNK Therapeutics, Inc. (INKT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for INKT are available on the INKT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own INKT?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling INKT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of MiNK Therapeutics, Inc.'s investment landscape.